Trefoil proteins: Their role in normal and malignant cells

Journal of Pathology

Volumn 183, Issue 1, 1997, Pages 4-7

  May, Felicity E B ^a,b   Westley, Bruce R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Cancer; hSP; ITF; Oestrogen; pS2; TFF 1; TFF 2; TFF 3; TFF domain; Trefoil domain protein

Indexed keywords

ESTROGEN; INTESTINAL TREFOIL FACTOR; MUCIN; TAMOXIFEN; TREFOIL PEPTIDE;

BREAST CANCER; CANCER CELL; CHEMOTAXIS; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT; GENE EXPRESSION; HORMONAL THERAPY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BREAST NEOPLASMS; ESTROGENS; FEMALE; GROWTH SUBSTANCES; HUMANS; MUCINS; MUSCLE PROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEUROPEPTIDES; PEPTIDES; PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 0030756408     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199709)183:1<4::AID-PATH1099>3.0.CO;2-5     Document Type: Review

References (52)

1. Poulsom R, Hanby AM, Lalani E-N, Hauser F, Huffman W, Stamp GWH. Intestinal trefoil factor (TFF3) and pS2 but not spasmolytic polypeptide mRNAs are co-expressed in normal, hyperplastic and neoplastic human breast epithelium. J Pathol 1997; 183: 30-38.
2. Poulsom R, Wright NA. Trefoil peptides: a newly recognised family of epithelial mucin-associated molecules. Am J Physiol: Gastrointestinal Liver Physiol 1993; 265: G205-G213.
3. Thim L. Trefoil peptides: a new family of gastrointestinal molecules. Digestion 1994; 55: 353-360.
4. Gajhede M, Petersen TN, Henriksen A. et al. Pancreatic spasmolytic polypeptide: first three-dimensional structure of a member of the mammalian trefoil family of peptides. Structure 1993; 1: 253-262.
5. Carr MD, Bauer CJ, Gradwell MJ, Feeney J. Solution structure of a trefoil-motif-containing cell growth factor, porcine spasmolytic protein. Proc Natl Acad Sci USA 1994; 91: 2206-2210.
6. De A, Brown DG, Gorman MA, Carr M, Sanderson MR, Freemont PS. Crystal structure of a disulfide-linked 'trefoil' motif found in a large family of putative growth factors. Proc Natl Acad Sci USA 1994; 91: 1084-1088.
7. Polshakov V, Williams MA, Gargaro AR, et al. High resolution structure of the human pNR-2/pS2 single domain trefoil peptide. J Mol Biol 1997; 267: 418-432.
8. Huffman W. A new repetitive protein from Xenopus laevis skin highly homologous to pancreatic spasmolytic polypeptide., J Biol Chem 1988; 262: 7686-7690.
9. Hauser F, Roeben C, Hoffmann W. xP2, a new member of the P-domain peptide family of potential growth factors, is synthesised in Xenopus laevis skin. J Biol Chem 1992; 267: 14451-14455.
10. Thim L, Woldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK. Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 1995; 34: 4757-4764.
11. Chinery R, Bates PA, De A, Freemont PS. Characterisation of the single cops trefoil peptides intestinal trefoil factor and pS2 and their ability to form covalent dimers. FEBS Lett 1995; 357: 50-54.
12. 58. Biochem J 1995; 308: 1001-1007.
13. Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterisation of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci USA 1991; 88: 11017-11021.
14. Hauser F, Poulsom R, Chinery R, et al. hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci USA 1993; 90: 6961-6965.
15. Rio MC, Bellocq JP, Daniel JY, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. 1988; 241: 705-707.
16. Hanby AM, Poulsom R, Singh S, Elia G, Jeffery RE, Wright NA. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology 1993; 105: 1110-1116.
17. Piggott NH, Henry JA, May FEB, Westley BR. Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J Pathol 1991; 163: 95-104.
18. Hirota M, Awatsuji H, Sugihara Y, Miyashita S, Furukawa Y, Hayashi K. Expression of pS2 gene in rat brain. Biochem Mul Biol Int 1995; 35: 1079-1084.
19. Probst JC, Skutella T, MullerSchmid A, Jirikowski GF, Hoffman W. Molecular and cellular analysis of rP1.B in the rat hypothalamus: in situ hybridisation and immunohistochemistry of a new P-domain neuropeptide. Mol Brain Res 1995; 33: 269-276.
20. Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK. Trefoil peptides promote epithelial migration through a transforming growth factor β-pathway. J Clin Invest 1994; 94: 376-383.
21. Williams R, Stamp GWH, Gilbert C, Pignatelli M, Lalani E-N. pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3D collagen gel. J Cell Sci 1996; 109: 63-71.
22. Playford RJ, Marchbank T, Chinery R, Thim L, Hanby AH. Human spasmolytic polypeptide is a cryoprotective agent which stimulates cell migration. Gastroemerology 1995; 108: 108-116.
23. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982; 10: 7895-7903.
24. May FEB, Westle BR. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res 1986; 46: 6034-6040.
25. Henry JA, Piggott NH, Mallick UK, et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 1991; 63: 615-622.
26. Henry JA, Bennet MK, Piggott NH, Levett DL, May FEB, Westley BR. Expression of pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 1991; 64: 677-682.
27. Theisinger B, Welter C, Seitz G, et al. Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur J Cancer 1991; 27: 770-773.
28. Welter C, Theisinger B, Seitz G, et al. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 1992; 66: 187-192.
29. Collier JD, Bennet MK, Bassendine MF, Lendrum R. Immunolocalisation of pS2, a putative growth factor, in pancreatic carcinoma. J Gastroenterol Hepatol 1995; 10: 396-400.
30. Tomasetto C, Rio M-C, Gautier C, et al. hSP, the domain duplicated homologue of pS2 protein, is coexpressed with pS2 in stomach but not in breast carcinoma. EMBO J 19XX; 9: 407-414.
31. Seitz G, Theisinger B, Tomasetto C, et al. Breast-cancer-associated protein pS2 expression in tumours of the biliary tract. Am J Gastroenterol 1991; 86: 1491-1494.
32. Taupin D, Ooi K, Yeomans N, Giraud A. Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest 1996; 75: 25-32.
33. Theisinger B, Seitz G, Dooley S, Welter C. A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer. Breast Cancer Res Treatment 1996; 38: 145-151.
34. May FEB, Westley BR. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol 1997; 182: 404-413.
35. Lefebvre O, Chenard M-P, Masson R, et al. Gastric mucosa abnormalities and tumourigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-262.
36. Wright NA, Poulsom R, Stamp GWH, et al. Epidermal growth factor (EGF/URO) induces expression of genes encoding regulatory peptides in damaged human gastrointestinal tissues. J Pathol 1990; 162: 279-284.
37. Taupin DR, Cook GA, Yeomans ND, Giraud AS. Increased trefoil peptide expression occurs late in the healing phase in a model of gastric ulceration in the rat. Gastroenterology 1994; 106: A195.
38. Chinery R, Playford RJ. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci 1995; 88: 401-403.
39. Babyatsky MW, de Baumont M, Thim L, Podolsky DK. Oral trefoil peptides protect against ethanol and indomethacin induced gastric injury in rats. Gastroenterology 1996; 110: 489-497.
40. Playford RJ, Marchbank T, Goodlad RA, et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 1996; 93: 2137-2142.
41. Mashimo H, Wu D-C, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274: 262-265.
42. Poulsom R, Chinery R, Sarraf C, et al. Trefoil peptide gene expression in small intestinal Crohn's disease and dietary adaptation. J Clin Gastroenterol 1993; 17: S78-S91.
43. McGuire WL (ed.). Hormone Receptors and Human Breast Cancer. New York: Raven Press, 1987.
44. Chinery R, Cox HM. Immunoprecipitation and characterisation of a binding protein specific for the peptide, intestinal trefoil factor. Peptides 1995; 16: 749-755.
45. Smith DB, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987; 23: 979-982.
46. Harris M, Howell A, Chrissohou M, Swindell RIC, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 1984; 50: 23-30.
47. Schwartz LH, Koerner FC, Edgerton SM, et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991; 51: 624-628.
48. Foekens JA, Potengan H, Look MP, et al. Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994; 70: 1217-1223.
49. McClelland RA, Manning DL, Gee JMW, et al. Effects of short-term antioestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treatment 1996; 41: 31-41.
50. Wilson YG, Rhodes M, Ibrahim NBM. Immunocytochemical staining of pS2 protein in fine-needle aspirates from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg 1994; 81: 1155-1158.
51. Soubeyran I, Quenel N, Coindre J-M, et al. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 1996; 74: 1120-1125.
52. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; ii: 104-107.